The aim of this study was to compare demographics, comorbidities, pulmonary function, and mortality between individuals with IPF with high (≥ 1:160) or low (< 1:160) ANA titers, in order to further investigate the potential impact of ANA positivity on disease outcomes. This evidence concerns the gene BTG3 and idiopathic pulmonary fibrosis.